Amylin analogue · human trial research
What is Cagrilintide?
Cagrilintide is an analogue of amylin, a hormone involved in signals associated with eating and fullness. It is not simply another name for semaglutide. The two compounds work through different hormone systems.
How does Cagrilintide work?
Amylin-related signalling provides a separate way to investigate appetite regulation. Research examines cagrilintide alone and in combination with other medicines. The combination of cagrilintide and semaglutide is commonly called CagriSema. [1]
What does the research show?
A 2021 phase 2 randomised trial studied 706 participants with overweight or obesity over 26 weeks. Cagrilintide groups showed greater average weight reduction than placebo. The trial also examined tolerability, including gastrointestinal symptoms. [1]
What the evidence does not establish
Evidence for a combination cannot be attributed entirely to cagrilintide alone. The formulation, comparator and participant selection all affect interpretation. This example is one study, not a complete current development history.
Safety questions to discuss
Ask which exact formulation and trial support a claim, and distinguish study participation from independently supplied products. [2]
Frequently asked questions
Is cagrilintide a GLP-1 receptor agonist?
It is an amylin analogue, which is a different hormone-related mechanism.
Is cagrilintide the same as CagriSema?
No. CagriSema refers to cagrilintide combined with semaglutide.
Sources and further reading
- Cagrilintide for weight management — randomised phase 2 trial, 2021
- SAHPRA: peptide products public information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.